Related references
Note: Only part of the references are listed.Fighting Immune Cold and Reprogramming Immunosuppressive Tumor Microenvironment with Red Blood Cell Membrane-Camouflaged Nanobullets
Zhe Yang et al.
ACS NANO (2020)
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
Xiaoyun Li et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Qian Chen et al.
NATURE NANOTECHNOLOGY (2019)
Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy
Hathaichanok Phuengkham et al.
ADVANCED MATERIALS (2019)
Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade
Shuangjiang Yu et al.
ADVANCED MATERIALS (2018)
Targeted and Off-Target (Bystander and Abscopal) Effects of Radiation Therapy: Redox Mechanisms and Risk/Benefit Analysis
Jean-Pierre Pouget et al.
ANTIOXIDANTS & REDOX SIGNALING (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
Chao Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu et al.
NATURE (2018)
CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer
Alex D. Michaels et al.
CLINICAL CANCER RESEARCH (2018)
Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22phox-derived reactive oxygen species in acute myeloid leukemia
Jennifer N. Moloney et al.
LEUKEMIA RESEARCH (2017)
Microenvironmental autophagy promotes tumour growth
Nadja S. Katheder et al.
NATURE (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model
Hua Tao et al.
ONCOLOGY RESEARCH (2017)
Adrenergic nerves activate an angio-metabolic switch in prostate cancer
Ali H. Zahalka et al.
SCIENCE (2017)
Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy
Yuting Huang et al.
JOURNAL OF THORACIC DISEASE (2017)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade (vol 29, pg 285, 2016)
Haidong Tang et al.
CANCER CELL (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Andy J. Minn et al.
CELL (2016)
Targeting human melanoma neoantigens by T cell receptor gene therapy
Matthias Leisegang et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Jonathan T. Sockolosky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
Mahnaz Mellati et al.
DIABETES CARE (2015)
Carvedilol use is associated with reduced cancer risk: A nationwide population-based cohort study
Chin-Sheng Lin et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
CD47 blockade as another immune checkpoint therapy for cancer
Robert H. Vonderheide
NATURE MEDICINE (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
Yu Zhu et al.
CANCER RESEARCH (2014)
New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape
Deepak Mittal et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Drug delivery vehicles on a nano-engineering perspective
Betiana Felice et al.
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?
Hisataka Kobayashi et al.
THERANOSTICS (2014)
Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?
Simran S. Sabharwal et al.
NATURE REVIEWS CANCER (2014)
A Reactive Oxygen Species (ROS)-Responsive Polymer for Safe, Efficient, and Targeted Gene Delivery in Cancer Cells
Min Suk Shim et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Autonomic Nerve Development Contributes to Prostate Cancer Progression
Claire Magnon et al.
SCIENCE (2013)
Beyond oxidative stress: an immunologist's guide to reactive oxygen species
Carl Nathan et al.
NATURE REVIEWS IMMUNOLOGY (2013)
CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest
E. Sick et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
Badreddin Edris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer
Amal Melhem-Bertrandt et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Perspective on Cancer Cell Metastasis
Christine L. Chaffer et al.
SCIENCE (2011)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines
D. Scott Wilson et al.
NATURE MATERIALS (2010)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Cancer-Related Axonogenesis and Neurogenesis in Prostate Cancer
Gustavo E. Ayala et al.
CLINICAL CANCER RESEARCH (2008)
Species- and cell type-specific interactions between CD47 and human SIRPα
S Subramanian et al.
BLOOD (2006)
Share Paper
